A Phase II, Randomised, Open-Label, Multicentre Study of AS1402 in Combination with Letrozole as First Line Treatment in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer.

Registry ID

EUCTR2008-001806-17

Source registry

EUCTR

Status

Ongoing

Phase

PHASE2

Sponsor

Antisoma Research Limited

Start date

2008-10-09

Last update

2026-08-16

Conditions

• Locally Advanced or Metastatic Breast Cancer

Summary

The overall objectives of this study are to compare the efficacy, safety and tolerability of AS1402 in combination with letrozole to letrozole alone as first-line treatment in post menopausal women with locally advanced or metastatic breast cancer. The primary objective is to compare the overall tumour response rate per RECIST in postmenopausal women with metastatic or locally advanced advanced breast cancer receiving AS1402 in combination with letrozole compared to letrozole alone

Locations

• , , France
• , , Poland

Related clinical trials

• A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
• The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.
• A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
• YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
• Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
• Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

View on source registry